MedTrace Logo

Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women

NCT00930137 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2013-03-05

No results posted yet for this study

Summary

While the deleterious effects of trans fat from industrial sources (iTFA) on cardiovascular health are well established, the impact of TFA from ruminants (rTFA) on cardiovascular risk factors has not been as well characterized. We have previously shown in men that a very high dietary intakes of rTFA (\>3.5% of energy) leads to unfavourable changes in lipid cardiovascular risk factors that are similar to those seen with iTFA. However, our data also indicated that achievable intakes of rTFA that remain well above the current human consumption (1.5% of energy intake) had neutral effects on plasma lipids and other cardiovascular disease (CVD) risk factors in men. Other studies have also suggested that the LDL and HDL response to very high dietary intakes of rTFA (\>5% of energy) in women may be different than in men.

The general objective of the study is to investigate for the first time in a double-blind randomized controlled study the impact of high but yet achievable intake of ruminant trans fatty acids on plasma LDL-Cholesterol and other risk factors for CVD in healthy women.

Conditions

Interventions

OTHER

isocaloric for week diet

Consumption of the 2 experimental diets 1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal); 2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).

Sponsors & Collaborators

  • Institute of Nutraceuticals and Functional Foods

    collaborator OTHER

  • Dairy Farmers of Canada

    collaborator OTHER

  • Dairy Australia

    collaborator INDUSTRY

  • Laval University

    lead OTHER

Principal Investigators

  • Benoît Lamarche, PhD · Institute of Nutraceutical and Functional Foods (INAF), Laval University

  • Patrick Couture, MD, FRCP (C, PhD) · Faculty of Medicine, Laval University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-12-31
Completion
2011-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930137 on ClinicalTrials.gov